HemoShear works with pharmaceutical companies in research collaborations combining its scientific expertise with its proprietary technology to identify and validate new drug targets and to de-risk drug discovery and development decisions.
HemoShear’s proprietary technology combines important physiological parameters to recreate in vivo biology on the bench top and provide insights that are far more predictive of human response than current methods used in the laboratory. HemoShear’s scientists have expertise across a broad number of areas, including:
- Human and animal biology,
- Bioinformatics and molecular profiling for target identification and validation,
- Sophisticated methods to quantify target genes and proteins,
- Cell signaling pathway analysis,
- Determination of mechanisms of action for efficacy and safety,
- Assessment of molecular pharmacology,
- Assessment of cell functional response.
This expertise enables HemoShear to design, conduct, and analyze scientific experiments using HemoShear's technology and provide to HemoShear’s customers important and previously unobtainable information on human responses much earlier in the drug R&D process.
HemoShear can help pharmaceutical and biotech companies save time and money by providing data that is far more reliable than data generated by current in-vitro methods. Experiments and analysis of data are conducted at HemoShear’s own laboratory operations in Charlottesville, Virginia, USA.
HemoShear’s customers gain competitive advantages through
- Faster discovery of novel drug targets,
- Discovery of innovative drug compounds,
- Comprehensive understanding of the effects of drugs on the vasculature or other organ system(s),
- Discovering new indications for existing compounds,
- Development of proprietary surrogate human organ and disease systems,
- Development of proprietary surrogate animal organ and disease systems.